奥沙利铂联合卡培他滨治疗晚期胃癌临床观察

目的 观察奥沙利铂联合卡培他滨治疗晚期胃癌的疗效及毒副作用.方法 35例确诊为晚期胃癌患者采用奥沙利铂联合卡培他滨方案化疗,奥沙利铂130 mg/m2,静脉滴注2h,第1天；卡培他滨2500 mg/m2,分2次口服,第1 ～14 d,21 d为1个周期,2个周期后评价疗效.结果 全组完全缓解(CR)2例,部分缓解(PR) 17例,稳定(SD) 10例,进展(PD)6例,总有效率(CR+ PR)54.3％,肿瘤控制率(CR+PR+SD)82.9％,中位生存时间11.5个月,1年生存率40.0％.主要不良反应有骨髓抑制、外周神经毒性、胃肠道反应、手足综合征等.结论 奥沙利铂联合卡培他滨治疗晚期胃癌有一定疗效,患者耐受性良好,值得推广.

The clinical observation of Oxaliplatin combined with Capecltabine in the treatment of advanced gastric cancer

Objective To evaluate the efficacy and toxicity of oxaliatin combined with capechabine in treatment of advanced gastric cancer. Methods Thirty-five patients with advanced gastric cancer were enoued into this study. They. received 2h intravenous infusion of oxaliplatin 130mg/m^2 on day 1 and oral administration of capecitabine 2500/m^2 ,given in two daily doses,on day 1 - 14. The regimen was repeated every 21 days. They were treated for two cycles. Results 2 patients achieved CR, 17 patients achieved PR, 10 patients achieved SD,6 patients achieved PD, the overall response rate （CR ＋ PR） was 54.3%, and the disease control rate （ CR ＋ PR ＋ SD） was 82.9%, median survival time was 11.5 months. One-year survival rate was 42.0%. The most common adverse events were myelosup- pression peripheral neuropathy, diarrhea, nausea/vomiting, and hand-foot syndrome. Conclusion Chemotherapy of oxaliplatin combined capeeitabin is effective and well toleraled to the patients with advanced gastric cancer. It is worthy of further clinical research.